Research

• Tissue Banking & Cohorts Theme
• Contacts
• Public Involvement in Tissue Banking and Cohorts.
• Video Library
• Key Publications

Inflammatory Bowel Disease Cohort

Inflammatory bowel disease (IBD) is heterogenous in nature and while some patients are lucky enough to experience a reasonably mild illness that remains in remission for long periods others may be troubled with multiple flare-ups, hospital admissions, and surgical operations. The project is involved in more closely defining the genetic and general molecular features of subgroups of IBD patients that are associated with relapses and remissions and response to different types of treatments. Hand in hand with these studies is the development of new molecular platforms and technologies that might be used to predict disease course and response to treatments in IBD.

This cohort also works closely with gastro immunology research into Crohn’s disease and ulcerative colitis.

Objectives:

• Harness a prospective cohort of 2,500 patients with clinically and genetically highly characterised IBD.

• Establish electronic database and biobank of cells, tissues, and body fluids for research into natural history, pathogenesis, and treatment of IBD.

• Provide infrastructure for translational research in IBD.

Cohort Description:

Established in 2009, it has enrolled 1131 patients (Jan 2012) who are consented for biobanking of tissues, as well as phenotype and genotype recall for clinical studies.

The cohort consists of all patients with IBD treated in the Oxford University Hospitals NHS Trust Hospitals, including:

• Children with IBD.

• Those with concomitant liver disease.

• Those with severe disease necessitating stoma surgery.

• Those undergoing ileo-anal pouch surgery.

• Those with intestinal failure.

The Crohn’s disease and ulcerative colitis research has:

• DNA from more than 1100 patients and controls.

• Serum samples and PBMC from just under 100 volunteers.

• Complete genotyping of the above using CD susceptibility chip.

Collaborations:

The cohort protocol forms basis of multiple collaborations with leading Pharma industry partners, including basic science studies of microbiome in IBD, biomarkers for IBD, role of IL-10 in IBD, phase II experimental medicine study based in Oxford, and continuing clinical development of Biotech-derived first-in-class chemokine receptor antagonist.

Publications: For key publications click here.

Principal Investigators: Dr Satish Keshav / Dr Alison Simmons.

Get involved:

Want to know more about the project? Contact Judith.Divino@orh.nhs.uk.
Want to know more about other volunteers’ experiences? Click here.

Contact:

Address: Translational Gastroenterology Unit, IBD Cohort Office, Level 5, John Radcliffe Hospital, OX3 9DU Tel: 01865 228772 or221428 Email: Judith Divino Judith.Divino@orh.nhs.uk, Dr Satish Keshav: Satish.Keshav@ndm.ox.ac.uk or Dr Alex Kent: Alex.Kent@ndm.ox.ac.uk.